Ángel Luis M.
- Country
- Spain
- Department
- Psychiatry
Research Overview
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Azetukalner in Patients with Bipolar Depression
- A Long-term, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Azetukalner in Patients with Bipolar I or II Depression
- Efficacy of Pegipanermin (XPro1595) in Early Alzheimer's Disease with Inflammatory Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 174 of 329 partner sites.
Specializations
Neurodegenerative Disorders
This investigator specializes in early Alzheimer's disease research, with particular emphasis on evaluating novel therapeutic approaches for cognitive decline and disease progression.
- Early-stage Alzheimer's interventions
- Mild cognitive impairment
- Cognitive performance assessment
The research encompasses various treatment modalities targeting different aspects of Alzheimer's pathology.
Psychiatric Conditions
The investigator conducts research in treatment-resistant depression and psychosis associated with Alzheimer's disease, exploring innovative therapeutic solutions.
- Neuropsychiatric symptoms in Alzheimer's
- Depression management
- Schizophrenia treatments
Their work includes evaluation of both traditional and novel therapeutic approaches for complex psychiatric conditions.
Specialized Therapeutic Areas
Focus areas include inflammatory biomarkers in Alzheimer's disease and assessment of various treatment delivery methods.
- Long-term safety evaluations
- Neuroinflammatory processes
- Clinical efficacy assessments
The investigator's work encompasses both oral and intravenous therapeutic interventions for neurological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.